Quarterly report [Sections 13 or 15(d)]

LICENSES ACQUIRED (Details)

v3.25.2
LICENSES ACQUIRED (Details)
$ in Millions, ¥ in Billions
 1 Months Ended
Nov. 11, 2024
USD ($)
Aug. 31, 2023
USD ($)
Aug. 31, 2023
CNY (¥)
Jun. 29, 2021
USD ($)
Jan. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Jul. 31, 2020
USD ($)
Assets and Licenses Acquired              
Percentage of license 4.00%            
Amzeeq              
Assets and Licenses Acquired              
Percentage of license         4.00%    
Zilxi              
Assets and Licenses Acquired              
Percentage of license         1.50%    
Emrosi Agreement              
Assets and Licenses Acquired              
Total Upfront payment       $ 10.0      
Upfront payment upon execution       3.0      
Remaining upfront payment       15.0      
Transformation of ownership and all assets of milestone payments       15.0      
Threshold additional contingent regulatory and commercial milestone payments payable       $ 150.0      
Percentage of reduction in royalty upon launching of competitor products       50.00%      
Emrosi Agreement | Minimum              
Assets and Licenses Acquired              
Percentage of royalties payable on net sales       10.00%      
Emrosi Agreement | Maximum              
Assets and Licenses Acquired              
Percentage of royalties payable on net sales       14.00%      
Asset purchase agreement | Qbrexza              
Assets and Licenses Acquired              
Age of patients           9 years  
Asset purchase agreement | Royalty payment percentage for first two years | Qbrexza              
Assets and Licenses Acquired              
Period of royalty payments           2 years  
Asset purchase agreement | Minimum | Royalty payment percentage for first two years | Qbrexza              
Assets and Licenses Acquired              
Percent of royalty payments           30.00%  
Asset purchase agreement | Minimum | Royalty payment percentage for thereafter | Qbrexza              
Assets and Licenses Acquired              
Percent of royalty payments           12.00%  
Asset purchase agreement | Maximum | Royalty payment percentage for first two years | Qbrexza              
Assets and Licenses Acquired              
Percent of royalty payments           40.00%  
Asset purchase agreement | Maximum | Royalty payment percentage for thereafter | Qbrexza              
Assets and Licenses Acquired              
Percent of royalty payments           19.00%  
Asset purchase agreement | Eli Lilly and Company | Qbrexza              
Assets and Licenses Acquired              
Upfront fees           $ 12.5  
Milestone payments payable           $ 144.0  
License and supply agreement With DRL | Accutane              
Assets and Licenses Acquired              
Amount of expense agreed to pay under the agreement             $ 5.0
Contingent amount payable             $ 17.0
Term of accutane             10 years
Termination accutane agreement period             180 days
New License Agreement              
Assets and Licenses Acquired              
Total Upfront payment   $ 19.0          
Amount of obligation payment terminated   10.0          
Remaining obligation payments   $ 45.0          
New License Agreement | Net sales of at least ¥4 billion (yen)              
Assets and Licenses Acquired              
Net sales | ¥     ¥ 4        
Cutia License Agreement | Amzeeq              
Assets and Licenses Acquired              
Milestone payment $ 1.0            
Other revenue 1.0            
Milestone payment received, net $ 1.0            
VYNE Product Acquisition Agreement              
Assets and Licenses Acquired              
Total Upfront payment         $ 450.0    
Upfront payment upon execution         5.0    
Upfront fees         20.0    
VYNE Product Acquisition Agreement | Amzeeq | First year anniversary              
Assets and Licenses Acquired              
Amount of expense paid under the agreement         10.0    
Net sales         100.0    
VYNE Product Acquisition Agreement | Amzeeq | Second year anniversary              
Assets and Licenses Acquired              
Amount of expense paid under the agreement         20.0    
Net sales         200.0    
VYNE Product Acquisition Agreement | Amzeeq | Third year anniversary              
Assets and Licenses Acquired              
Amount of expense paid under the agreement         30.0    
Net sales         300.0    
VYNE Product Acquisition Agreement | Amzeeq | Fourth year anniversary              
Assets and Licenses Acquired              
Amount of expense paid under the agreement         40.0    
Net sales         400.0    
VYNE Product Acquisition Agreement | Amzeeq | Fifth year anniversary              
Assets and Licenses Acquired              
Amount of expense paid under the agreement         50.0    
Net sales         500.0    
VYNE Product Acquisition Agreement | Zilxi | First year anniversary              
Assets and Licenses Acquired              
Amount of expense paid under the agreement         10.0    
Net sales         100.0    
VYNE Product Acquisition Agreement | Zilxi | Second year anniversary              
Assets and Licenses Acquired              
Amount of expense paid under the agreement         20.0    
Net sales         200.0    
VYNE Product Acquisition Agreement | Zilxi | Third year anniversary              
Assets and Licenses Acquired              
Amount of expense paid under the agreement         30.0    
Net sales         300.0    
VYNE Product Acquisition Agreement | Zilxi | Fourth year anniversary              
Assets and Licenses Acquired              
Amount of expense paid under the agreement         40.0    
Net sales         400.0    
VYNE Product Acquisition Agreement | Zilxi | Fifth year anniversary              
Assets and Licenses Acquired              
Amount of expense paid under the agreement         50.0    
Net sales         $ 500.0